Neuronal Regulatory Elements for CNS-Selective Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy technologies face challenges in specifically targeting therapeutic interventions to affected cellular populations, leading to off-target effects and reduced efficacy.
Innovation Solution
The use of genetic regulatory elements, such as specific nucleotide sequences (SEQ ID NOs: 1-13) and vectors, including AAV and adenovirus vectors, to selectively express heterologous nucleotide sequences in neurons of the central nervous system, minimizing expression in non-neuronal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic regulatory elements are used to restrict therapeutic intervention to specific cellular populations, then off-target effects are reduced and therapeutic efficacy is increased, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The vector is segmented into distinct functional modules: a promoter region, the genetic regulatory element (tissue-specific sequence), and the heterologous nucleotide sequence. This modular segmentation allows each component to be optimized independently while maintaining overall functionality, resolving the contradiction between achieving high specificity and managing vector complexity
Solution Approach 2:
The genetic regulatory element serves multiple functions: it acts as a promoter, a tissue-specific selector, and an expression controller simultaneously. This multi-functionality reduces the need for separate regulatory components, thereby reducing overall vector complexity while maintaining high therapeutic efficacy through restricted expression
2Object-affected harmful factors
If genetic regulatory elements are used to restrict therapeutic intervention to specific cellular populations, then off-target effects are reduced and therapeutic efficacy is increased, but ease of manufacture decreases
Solution Approach 1:
The regulatory element introduces local quality control to the vector by confining therapeutic expression specifically to target tissues (e.g., CNS neurons). This localized expression control eliminates off-target effects in non-target tissues while maintaining straightforward manufacturing processes, as the regulatory sequence is integrated into the vector backbone without requiring complex post-manufacturing modifications
3Manufacturing precision
If tissue-specific regulatory elements are implemented, then expression specificity is improved, but the complexity of achieving selective expression increases
Solution Approach 1:
The tissue-specific regulatory function is extracted from complex cellular control mechanisms and encapsulated into a discrete, transferable DNA sequence element. This extracted regulatory element can be easily inserted into vectors and achieves precise tissue-specific expression without requiring the full complexity of natural gene regulation systems
Solution Approach 2:
The regulatory element changes the expression parameter from constitutive (always on) to tissue-specific (conditionally on). This parameter change is achieved through the inherent properties of the tissue-specific promoter sequence, which responds to tissue-specific transcription factors, thereby achieving high expression specificity without adding complex control mechanisms
Data Source
AI summary
Provided herein are regulatory elements capable of restricting the expression of a heterologous nucleotide sequence to specific neuronal populations and regions of the central nervous system (CNS). Further provided herein are vectors comprising such regulatory elements and uses of such regulatory elements and vectors for selective expression in the CNS.